Bristol-Myers Squibb Company BMY today announced new 4-year results
from the long-term extensions (LTE) of the BENEFIT and BENEFIT-EXT clinical
trials of NULOJIX® (belatacept), the first selective T-cell costimulation
blocker indicated for the prophylaxis of organ rejection in adult Epstein-Barr
Virus (EBV) seropositive patients receiving a kidney transplant, in
combination with basiliximab induction, mycophenolate mofetil (MMF), and
corticosteroids. Results showed that the safety profile of NULOJIX through
year 4 was consistent compared with results at year 3 with no new safety
signals being identified, and that the renal function benefit versus
cyclosporine was maintained through 4 years in patients enrolled in the LTE
from both the BENEFIT and BENEFIT-EXT trials. The new data were presented in
oral sessions at the 2012 American Transplant Congress (ATC) in Boston.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in